Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) EBT (2022 - 2026)

TriSalus Life Sciences has reported EBT over the past 5 years, most recently at $1.5 million for Q1 2026.

  • For Q1 2026, EBT rose 114.88% year-over-year to $1.5 million; the TTM value through Mar 2026 reached -$27.3 million, changed 0.37%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • EBT for Q1 2026 was $1.5 million at TriSalus Life Sciences, up from -$9.8 million in the prior quarter.
  • Over five years, EBT peaked at $2.8 million in Q1 2022 and troughed at -$35.6 million in Q4 2023.
  • A 5-year average of -$9.0 million and a median of -$8.3 million in 2025 define the central range for EBT.
  • Biggest five-year swings in EBT: plummeted 678.23% in 2023 and later soared 114.88% in 2026.
  • Year by year, EBT stood at -$22.5 million in 2022, then tumbled by 58.14% to -$35.6 million in 2023, then surged by 71.63% to -$10.1 million in 2024, then increased by 3.52% to -$9.8 million in 2025, then soared by 115.82% to $1.5 million in 2026.
  • Business Quant data shows EBT for TLSI at $1.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$10.8 million in Q3 2025.